Patents by Inventor Michelle O'Donnell

Michelle O'Donnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11896628
    Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: February 13, 2024
    Assignee: Artugen Therapeutics Ltd.
    Inventors: Ronald Farquhar, Christopher K. Murphy, Colin Hill, Paul Ross, Mary Rea, Michelle O'Donnell, Brian Healy, Laurent Chesnel
  • Publication number: 20230132133
    Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.
    Type: Application
    Filed: July 1, 2022
    Publication date: April 27, 2023
    Applicant: Artugen Therapeutics Ltd.
    Inventors: Ronald Farquhar, Christopher K. Murphy, Colin Hill, Paul Ross, Mary Rea, Michelle O'Donnell, Brian Healy, Laurent Chesnel
  • Patent number: 11419900
    Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: August 23, 2022
    Assignee: Artugen Therapeutics Ltd.
    Inventors: Ronald Farquhar, Christopher K. Murphy, Colin Hill, Paul Ross, Mary Rea, Michelle O'Donnell, Brian Healy, Laurent Chesnel
  • Publication number: 20210220411
    Abstract: Disclosed herein are compositions and methods for preventing, ameliorating, or treating Clostridium difficile infections and/or reducing the severity of one or more risk factors, signs, or symptoms associated with C. difficile infections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains of Bacillus amyloliquefaciens bacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk for C. difficile infections.
    Type: Application
    Filed: June 6, 2019
    Publication date: July 22, 2021
    Inventors: Ronald Farquhar, Christopher K. Murphy, Colin Hill, Paul Ross, Mary Rea, Michelle O'Donnell, Brian Healy, Laurent Chesnel